Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-CTEPH
2024-513672-17-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of macitentan and riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Pulmonary vascular resistance at rest at week 16. Started Nov 2024; status: completed.
02
Drugs
macitentanriociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2024-513672-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513672-17-00.